Hua Ou1, Qi Yu2. 1. Medical Examination Center, China-Japan Friendship Hospital, Beijing, China. 2. Department of Gynecology and Obstetrics, Chinese Academy of Medical Sciences, Peking Union Medical College Hospital, Beijing, China.
Abstract
OBJECTIVE: To assess the efficacy of aspirin, prednisone, and multivitamin triple therapy in treating unexplained recurrent spontaneous abortion (URSA). METHODS: Data were reviewed from women with early RSA attending a hospital in Beijing, China, 2013-2017. Those with no abnormal indices (e.g., endocrine, coagulation, immune, genetic) were diagnosed as having URSA, and received aspirin, prednisone, and multivitamin therapy (triple therapy group, n=106) or folic acid monotherapy (control group, n=65). Treatment efficacy was evaluated as the rate of successful treatment (12-week pregnancy with obvious embryo and embryonic heart, nuchal translucency thickness <0.25 cm, size consistent with gestational age, no early malformation). RESULTS: Overall, 362 women had early RSA and 171 (47.2%) had URSA. The rate of successful pregnancy was similar between the triple therapy (89.6%) and control (92.3%) groups (P=0.343). The rate of successful treatment was higher in the triple therapy (86.3%) than in the control (53.3%) group (P<0.001). In multivariate logistic regression analysis, triple therapy was associated with higher odds of successful treatment, whereas the number of spontaneous pregnancy losses was associated with lower odds of successful treatment. CONCLUSION: The triple therapy of aspirin, prednisone, and multivitamin was found to be a good treatment option for women with URSA.
OBJECTIVE: To assess the efficacy of aspirin, prednisone, and multivitamin triple therapy in treating unexplained recurrent spontaneous abortion (URSA). METHODS: Data were reviewed from women with early RSA attending a hospital in Beijing, China, 2013-2017. Those with no abnormal indices (e.g., endocrine, coagulation, immune, genetic) were diagnosed as having URSA, and received aspirin, prednisone, and multivitamin therapy (triple therapy group, n=106) or folic acid monotherapy (control group, n=65). Treatment efficacy was evaluated as the rate of successful treatment (12-week pregnancy with obvious embryo and embryonic heart, nuchal translucency thickness <0.25 cm, size consistent with gestational age, no early malformation). RESULTS: Overall, 362 women had early RSA and 171 (47.2%) had URSA. The rate of successful pregnancy was similar between the triple therapy (89.6%) and control (92.3%) groups (P=0.343). The rate of successful treatment was higher in the triple therapy (86.3%) than in the control (53.3%) group (P<0.001). In multivariate logistic regression analysis, triple therapy was associated with higher odds of successful treatment, whereas the number of spontaneous pregnancy losses was associated with lower odds of successful treatment. CONCLUSION: The triple therapy of aspirin, prednisone, and multivitamin was found to be a good treatment option for women with URSA.